Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 4708076, 9 pages
https://doi.org/10.1155/2017/4708076
Review Article

The Role of PDGFs and PDGFRs in Colorectal Cancer

1First Medical Clinic, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca, 3-5 Clinicilor Street, 400006 Cluj-Napoca, Romania
2Department of Functional Genomics, Proteomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania
3The Regional Institute of Gastroenterology and Hepatology “Prof. Dr. Octavian Fodor” Cluj-Napoca, 5 Constanta Street, 400158 Cluj-Napoca, Romania
4Department of Surgical and Gynecological Oncology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania
5Department of Surgery, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania

Correspondence should be addressed to Cosmin Lisencu; moc.oohay@ucnesilnimsoc and Ovidiu Balacescu; or.ncoi@ucsecalabuidivo

Received 14 September 2016; Revised 4 November 2016; Accepted 8 December 2016; Published 10 January 2017

Academic Editor: Antonio Macciò

Copyright © 2017 Roberta M. Manzat Saplacan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Leslie, F. A. Carey, N. R. Pratt, and R. J. C. Steele, “The colorectal adenoma-carcinoma sequence,” British Journal of Surgery, vol. 89, no. 7, pp. 845–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Burch, K. Soares-Weiser, D. J. B. St John et al., “Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review,” Journal of Medical Screening, vol. 14, no. 3, pp. 132–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Hanahan and L. M. Coussens, “Accessories to the crime: functions of cells recruited to the tumor microenvironment,” Cancer Cell, vol. 21, no. 3, pp. 309–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. O'Toole, A. J. Michielsen, B. Nolan et al., “Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive,” British Journal of Cancer, vol. 111, no. 5, pp. 927–932, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Cao, “Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis,” Trends in Molecular Medicine, vol. 19, no. 8, pp. 460–473, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Folkman, “Fundamental concepts of the angiogenic process,” Current Molecular Medicine, vol. 3, no. 7, pp. 643–651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Carmeliet, “Angiogenesis in life, disease and medicine,” Nature, vol. 438, no. 7070, pp. 932–936, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. K. A. Rmali, M. C. A. Puntis, and W. G. Jiang, “Tumour-associated angiogenesis in human colorectal cancer,” Colorectal Disease, vol. 9, no. 1, pp. 3–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Ramakrishnan, V. Anand, and S. Roy, “Vascular endothelial growth factor signaling in hypoxia and inflammation,” Journal of Neuroimmune Pharmacology, vol. 9, no. 2, pp. 142–160, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. C. W. Pugh and P. J. Ratcliffe, “Regulation of angiogenesis by hypoxia: role of the HIF system,” Nature Medicine, vol. 9, no. 6, pp. 677–684, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Mizukami, Y. Kohgo, and D. C. Chung, “Hypoxia inducible factor-1-independent pathways in tumor angiogenesis,” Clinical Cancer Research, vol. 13, no. 19, pp. 5670–5674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Homsi and A. I. Daud, “Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors,” Cancer Control, vol. 14, no. 3, pp. 285–294, 2007. View at Google Scholar · View at Scopus
  13. J. E. Peterson, D. Zurakowski, J. E. Italiano Jr. et al., “VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients,” Angiogenesis, vol. 15, no. 2, pp. 265–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. Bruhn, A. R. Townsend, C. Khoon Lee et al., “Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer,” International Journal of Cancer, vol. 135, no. 3, pp. 731–741, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Ding, T. R. Knox, R. C. Tschumper et al., “Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch,” Blood, vol. 116, no. 16, pp. 2984–2993, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Kodama, Y. Kitadai, T. Sumida et al., “Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma,” Cancer Science, vol. 101, no. 9, pp. 1984–1989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Xue, S. Lim, Y. Yang et al., “PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells,” Nature Medicine, vol. 18, no. 1, pp. 100–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Cao, M. A. Bjorndahl, P. Religa et al., “PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis,” Cancer Cell, vol. 6, no. 4, pp. 333–345, 2004. View at Google Scholar
  19. M. Potente, H. Gerhardt, and P. Carmeliet, “Basic and therapeutic aspects of angiogenesis,” Cell, vol. 146, no. 6, pp. 873–887, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. S. De Falco, “Antiangiogenesis therapy: an update after the first decade,” Korean Journal of Internal Medicine, vol. 29, no. 1, pp. 1–11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Fredriksson, H. Li, and U. Eriksson, “The PDGF family: four gene products form five dimeric isoforms,” Cytokine and Growth Factor Reviews, vol. 15, no. 4, pp. 197–204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. P.-H. Chen, X. Chen, and X. He, “Platelet-derived growth factors and their receptors: structural and functional perspectives,” Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1834, no. 10, pp. 2176–2186, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Tallquist and A. Kazlauskas, “PDGF signaling in cells and mice,” Cytokine and Growth Factor Reviews, vol. 15, no. 4, pp. 205–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Andrae, R. Gallini, and C. Betsholtz, “Role of platelet-derived growth factors in physiology and medicine,” Genes and Development, vol. 22, no. 10, pp. 1276–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Karlsson, P. Lindahl, J. K. Heath, and C. Betsholtz, “Abnormal gastrointestinal development in PDGF-A and PDGFR-α deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis,” Development, vol. 127, no. 16, pp. 3457–3466, 2000. View at Google Scholar · View at Scopus
  26. H. Boström, A. Gritli-Linde, and C. Betsholtz, “PDGF-A/PDGF alpha-receptor signaling is required for lung growth and the formation of alveoli but not for early lung branching morphogenesis,” Developmental Dynamics, vol. 223, no. 1, pp. 155–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Karlsson, C. Bondjers, and C. Betsholtz, “Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle,” Development, vol. 126, no. 12, pp. 2611–2621, 1999. View at Google Scholar · View at Scopus
  28. M. Fruttiger, L. Karlsson, A. C. Hall et al., “Defective oligodendrocyte development and severe hypomyelination in PDGF-A knockout mice,” Development, vol. 126, no. 3, pp. 457–467, 1999. View at Google Scholar · View at Scopus
  29. A. Hochhaus, P. D. Le Coutre, H. M. Kantarjian et al., “Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 12, pp. 1985–1993, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Ozawa, C. W. Brennan, L. Wang et al., “PDGFRA gene rearrangements are frequent genetic events in PDGFR-α-amplified glioblastomas,” Genes & Development, vol. 24, no. 19, pp. 2205–2218, 2010. View at Publisher · View at Google Scholar
  31. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFR-α, IDH1 EGFR, and NF1,” Cancer Cell, vol. 17, no. 1, pp. 98–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Medves, F. Duhoux, A. Ferrant et al., “KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia,” Leukemia, vol. 24, pp. 1052–1055, 2010. View at Publisher · View at Google Scholar
  33. L. He and K. Hristova, “Physical-chemical principles underlying RTK activation, and their implications for human disease,” Biochimica et Biophysica Acta—Biomembranes, vol. 1818, no. 4, pp. 995–1005, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. J.-B. Demoulin and A. Essaghir, “PDGF receptor signaling networks in normal and cancer cells,” Cytokine and Growth Factor Reviews, vol. 25, no. 3, pp. 273–283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. I. H. Pilz, G. Di Pasquale, A. Rzadzinska, S. H. Leppla, and J. A. Chiorini, “Mutation in the platelet-derived growth factor receptor alpha inhibits adeno-associated virus type 5 transduction,” Virology, vol. 428, no. 1, pp. 58–63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. I. D. Clarke and P. B. Dirks, “A human brain tumor-derived PDGFR-α deletion mutant is transforming,” Oncogene, vol. 22, no. 5, pp. 722–733, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. R. M. Manzat-Saplacan, L. Balacescu, C. Gherman et al., “Is there a correlation between peripheral blood expression of angiogenic transcriptional factors/receptors and colorectal cancer?” Journal of B.U.ON., vol. 20, no. 5, pp. 1193–1200, 2015. View at Google Scholar · View at Scopus
  38. S. Song, A. J. Ewald, W. Stallcup, Z. Werb, and G. Bergers, “PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival,” Nature Cell Biology, vol. 7, no. 9, pp. 870–879, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Sundberg, M. Ljungström, G. Lindmark, B. Gerdin, and K. Rubin, “Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma,” The American Journal of Pathology, vol. 143, no. 5, pp. 1377–1388, 1993. View at Google Scholar · View at Scopus
  40. Y. Kitadai, T. Sasaki, T. Kuwai et al., “Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential,” International Journal of Cancer, vol. 119, no. 11, pp. 2567–2574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. M. C. Heinrich, C. L. Corless, A. Duensing et al., “PDGFRα activating mutations in gastrointestinal stromal tumors,” Science, vol. 299, no. 5607, pp. 708–710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Appiah-Kubi, Y. Wang, H. Qian et al., “Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers,” Tumor Biology, vol. 37, no. 8, pp. 10053–10066, 2016. View at Publisher · View at Google Scholar
  43. U. McDermott, R. Y. Ames, A. J. Iafrate et al., “Ligand-dependent platelet-derived growth factor receptor (PDGFR)-α activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors,” Cancer Research, vol. 69, no. 9, pp. 3937–3946, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. E. J. A. Steller, D. A. Raats, J. Koster et al., “PDGFRβ promotes liver metastasis formation of mesenchymal-like colorectal tumor cells,” Neoplasia, vol. 15, no. 2, pp. 204–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Estevez-Garcia, A. Castaño, A. C. Martin et al., “PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome,” BMC Cancer, vol. 12, article 514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. T. C. Wehler, K. Frerichs, C. Graf et al., “PDGFRα/β expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy,” Oncology Reports, vol. 19, no. 3, pp. 697–704, 2008. View at Google Scholar
  47. P. Erben, K. Horisberger, B. Muessle et al., “mRNA expression of platelet-derived growth factor receptorbeta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 5, pp. 1544–1550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Yu, C. Ustach, and H.-R. C. Kim, “Platelet-derived growth factor signaling and human cancer,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 1, pp. 49–59, 2003. View at Google Scholar · View at Scopus
  49. M. Mantur, O. Koper, J. Snarska, A. Sidorska, and K. Kruszewska-Wnorowska, “Evaluation of PDGF-AB and sP-selectin concentrations in relation to platelet count in patients with colorectal cancer before and after surgical treatment,” Polskie Archiwum Medycyny Wewnetrznej, vol. 118, no. 6, pp. 345–350, 2008. View at Google Scholar · View at Scopus
  50. R. F. Doolittle, M. W. Hunkapiller, L. E. Hood et al., “Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor,” Science, vol. 221, no. 4607, pp. 275–277, 1983. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Hsu, F. Huang, and E. Friedman, “Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect,” Journal of Cellular Physiology, vol. 165, no. 2, pp. 239–245, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Ito, K. Yoshida, E. Kyo et al., “Expression of several growth factors and their receptor genes in human colon carcinomas,” Virchows Archiv B Cell Pathology Including Molecular Pathology, vol. 59, no. 1, pp. 173–178, 1990. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Ionescu, I. Berindan-Neagoe, C. Burz et al., “The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer,” Journal of B.U.ON., vol. 16, no. 2, pp. 274–276, 2011. View at Google Scholar · View at Scopus
  54. M. F. McCarty, R. J. Somcio, O. Stoeltzing et al., “Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content,” The Journal of Clinical Investigation, vol. 117, no. 8, pp. 2114–2122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Gerhardt and C. Betsholtz, “Endothelial-pericyte interactions in angiogenesis,” Cell and Tissue Research, vol. 314, no. 1, pp. 15–23, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Gaengel, G. Genové, A. Armulik, and C. Betsholtz, “Endothelial-mural cell signaling in vascular development and angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 5, pp. 630–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Belizon, E. Balik, P. K. Horst, H. M. C. S. Kumara, A. Nasar, and R. L. Whelan, “Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma,” Diseases of the Colon and Rectum, vol. 52, no. 6, pp. 1166–1171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. D. G. Gilbertson, M. E. Duff, J. W. West et al., “Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF α and β receptor,” Journal of Biological Chemistry, vol. 276, no. 29, pp. 27406–27414, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Cao, E. Bråkenhielm, X. Li et al., “Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors,” FASEB Journal, vol. 16, no. 12, pp. 1575–1583, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Yamauchi, S. Iida, M. Ishiguro, T. Ishikawa, H. Uetake, and K. Sugihara, “Clinical significance of platelet-derived growth factor-C expression in colorectal cancer,” Journal of Cancer Therapy, vol. 5, no. 1, pp. 11–20, 2014. View at Publisher · View at Google Scholar
  61. C. Anderberg, H. Li, L. Fredriksson et al., “Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts,” Cancer Research, vol. 69, no. 1, pp. 369–378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Zhao and A. A. Adjei, “Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor,” Oncologist, vol. 20, no. 6, pp. 660–673, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Carmeliet and R. K. Jain, “Molecular mechanisms and clinical applications of angiogenesis,” Nature, vol. 473, no. 7347, pp. 298–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. A. W. Griffioen, L. A. Mans, A. M. A. De Graaf et al., “Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients,” Clinical Cancer Research, vol. 18, no. 14, pp. 3961–3971, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Majumder, A.-C. Piguet, J.-F. Dufour, and S. Chatterjee, “Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis,” European Journal of Pharmacology, vol. 705, no. 1–3, pp. 86–95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Hamberg, J. Verweij, and S. Sleijfer, “(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor,” The Oncologist, vol. 15, no. 6, pp. 539–547, 2010. View at Publisher · View at Google Scholar · View at Scopus